- Home
- CHRS vs HMST Comparison
CHRS vs HMST Comparison
Compare CHRS & HMST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- HMST
- Stock Information
- Founded
- CHRS 2010
- HMST 1921
- Country
- CHRS United States
- HMST United States
- Employees
- CHRS N/A
- HMST N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- HMST Major Banks
- Sector
- CHRS Health Care
- HMST Finance
- Exchange
- CHRS Nasdaq
- HMST Nasdaq
- Market Cap
- CHRS 191.3M
- HMST 191.6M
- IPO Year
- CHRS 2014
- HMST 2012
- Fundamental
- Price
- CHRS $1.39
- HMST $10.84
- Analyst Decision
- CHRS Strong Buy
- HMST Buy
- Analyst Count
- CHRS 4
- HMST 2
- Target Price
- CHRS $5.38
- HMST $14.75
- AVG Volume (30 Days)
- CHRS 2.0M
- HMST 195.0K
- Earning Date
- CHRS 03-12-2025
- HMST 01-27-2025
- Dividend Yield
- CHRS N/A
- HMST N/A
- EPS Growth
- CHRS N/A
- HMST N/A
- EPS
- CHRS N/A
- HMST N/A
- Revenue
- CHRS $304,340,000.00
- HMST $169,710,000.00
- Revenue This Year
- CHRS $2.47
- HMST N/A
- Revenue Next Year
- CHRS N/A
- HMST $17.03
- P/E Ratio
- CHRS N/A
- HMST N/A
- Revenue Growth
- CHRS 44.19
- HMST N/A
- 52 Week Low
- CHRS $0.66
- HMST $8.09
- 52 Week High
- CHRS $2.97
- HMST $16.10
- Technical
- Relative Strength Index (RSI)
- CHRS 45.86
- HMST 49.99
- Support Level
- CHRS $1.38
- HMST $9.36
- Resistance Level
- CHRS $1.60
- HMST $11.99
- Average True Range (ATR)
- CHRS 0.13
- HMST 0.57
- MACD
- CHRS -0.03
- HMST 0.05
- Stochastic Oscillator
- CHRS 9.52
- HMST 53.24
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About HMST HomeStreet Inc.
HomeStreet Inc is a commercial bank. It provides commercial loans and consumer loans including mortgage loans, deposit products, private banking, and cash management services. The company loan products include commercial business loans and agriculture loans, consumer loans, single family residential mortgages, loans secured by commercial real estate and construction loans for residential and commercial real estate projects.